Cyclarity Therapeutics Launches Phase 1 Trial for Heart Disease Drug UDP-003 in Australia

January 13, 2025
Cyclarity Therapeutics Launches Phase 1 Trial for Heart Disease Drug UDP-003 in Australia
  • Dr. Matthew O’Connor, CEO of Scientific Affairs at Cyclarity, explained that delays in starting the trials were due to a backlog at the MHRA following Brexit.

  • Originally, the clinical trials were planned for Cambridge, UK, but the decision to relocate to Australia was made to streamline the process.

  • All required documentation for trial authorization has been submitted and approved, with the trial expected to begin shortly.

  • UDP-003 is designed to target 7-ketocholesterol, a detrimental oxidized cholesterol variant linked to atherosclerosis and heart disease, which is the leading cause of death worldwide.

  • The manufacturing process for UDP-003 has been completed in accordance with Current Good Manufacturing Practice (CGMP), ensuring the drug's quality and safety for human use.

  • This Phase 1 clinical study will evaluate the safety and preliminary efficacy of UDP-003, which includes a segment involving 12 patients with acute coronary syndrome.

  • If proven successful, UDP-003 could potentially reverse heart disease in 70-80% of patients, marking a significant improvement over existing treatments such as lifestyle changes and statins.

  • This trial represents a crucial milestone for Cyclarity, emphasizing the potential to tackle age-related diseases by addressing their root causes.

  • Cyclarity Therapeutics, a biotechnology firm located at the Buck Institute in California, has launched its inaugural human clinical trial for the candidate drug UDP-003.

  • The trials are set to take place at CMAX in Australia, in partnership with Monash University and overseen by Dr. Stephen Nicholls, a well-respected cardiologist.

Summary based on 1 source


Get a daily email with more Science stories

Source

Cyclarity Launches Human Trial for Atherosclerosis

Lifespan Extension Advocacy Foundation • Jan 13, 2025

Cyclarity Launches Human Trial for Atherosclerosis

More Stories